Seminars in Liver Disease

LinksSchließen

Referenz

Zhu AX, Park JO, Ryoo BY. , et al; REACH Trial Investigators.
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Lancet Oncol 2015;
16 (07) 859-870

Bibliographische Angaben herunterladen

Aufrufen in: